ADELAIDE, Australia / RankWire.AI / – Researchers in Australia have pinpointed a molecular switch that influences the spread of aggressive tumors, revealing a new potential treatment avenue to prevent secondary cancers. Published in EMBO Molecular Medicine, scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute showed that boosting levels of a crucial regulatory molecule known as miR-342 significantly curbs tumor dissemination. These insights suggest that Australian scientists are pioneering an innovative approach to address triple-negative breast cancer by targeting dormant cancer cells before they develop into threatening lesions in distant organs.
While triple-negative breast cancer makes up 10% to 15% of Australia’s roughly 21,000 annual breast cancer cases, it is responsible for a disproportionate share of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which makes standard hormone-targeted treatments ineffective. The lead researchers demonstrated that when miR-342 levels decrease, an oncogenic pathway called E2F becomes hyperactive. This activation allows dormant cancer cells to metastasize and establish secondary tumors throughout the body.
Innovative Targeted Treatments Offer New Opportunities for High-Risk Metastasis Prevention
Pre-clinical experiments showed that restoring miR-342 levels notably reduced the spread of cancer cells to distant organs. Additionally, researchers found that palbociclib, an approved CDK4/6 inhibitor currently used to treat hormone receptor-positive breast cancers, was effective at stopping metastatic tumor growth in models with low miR-342. These results suggest that assessing miR-342 levels could enable clinicians to repurpose existing drugs for high-risk patients.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, confirmed that preventing metastasis remains the key challenge in treating aggressive breast cancers. Gregory highlighted that because palbociclib targets the overactive E2F pathway, its use after cancer spread can prevent microscopic deposits from expanding. This therapeutic approach shifts focus from merely shrinking primary tumors to stopping microscopic secondary cancers from developing into life-threatening conditions.
Pre-Clinical Results Published in Reputable EMBO Molecular Medicine Journal
The research team pointed out that the biological diversity of triple-negative breast cancer has historically posed obstacles to developing universal targeted therapies. By identifying a specific biological vulnerability common to a subgroup of patients, this study paves the way for personalized treatment strategies. As Australian scientists explore a promising new method to combat triple-negative breast cancer, efforts are underway to validate these findings using patient-derived models before progressing to clinical trials.
Medical oncologists and cancer research agencies across Australia welcomed the findings, emphasizing the critical need for expanded treatment options when standard therapies fall short. The research team intends to work with international clinical networks to expedite biomarker screening procedures. Confirming the effectiveness of miR-342 testing could soon allow healthcare providers to identify suitable candidates for targeted CDK4/6 inhibitor treatments during early intervention stages.